Neurocrine Raises 2026 INGREZZA Sales Guidance to $2.9B–$2.925B
Neurocrine reported third-quarter 2026 revenue of $1.1 billion, up 41% year over year, and raised 2026 INGREZZA net sales guidance to $2.9 billion–$2.925 billion. The prior guidance range was not stated.
Story updates
10:16:49 PM UTC
SquawkNews
BRIEF-Neurocrine Biosciences - Ingrezza 2026 Net Sales Guidance Raised To $2.9 Billion-$2.93 Billion
Neurocrine reported third-quarter 2026 revenue of $1.1B, up 41% year over year, and raised 2026 INGREZZA net sales guidance to $2.9B—$2.925B; the prior guidance range was not stated in the release.Material DetailsContext by AI AnalystThis is a mid-cycle update combining quarterly growth with a rais…